IBDEI15G ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,18661,2)
;;=^5003026
;;^UTILITY(U,$J,358.3,18662,0)
;;=E11.9^^64^834^11
;;^UTILITY(U,$J,358.3,18662,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18662,1,3,0)
;;=3^DM Type 2 w/o Complications
;;^UTILITY(U,$J,358.3,18662,1,4,0)
;;=4^E11.9
;;^UTILITY(U,$J,358.3,18662,2)
;;=^5002666
;;^UTILITY(U,$J,358.3,18663,0)
;;=E10.9^^64^834^1
;;^UTILITY(U,$J,358.3,18663,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18663,1,3,0)
;;=3^DM Type 1 w/o Complications
;;^UTILITY(U,$J,358.3,18663,1,4,0)
;;=4^E10.9
;;^UTILITY(U,$J,358.3,18663,2)
;;=^5002626
;;^UTILITY(U,$J,358.3,18664,0)
;;=Z79.4^^64^834^14
;;^UTILITY(U,$J,358.3,18664,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18664,1,3,0)
;;=3^Long Term Use of Insulin
;;^UTILITY(U,$J,358.3,18664,1,4,0)
;;=4^Z79.4
;;^UTILITY(U,$J,358.3,18664,2)
;;=^5063334
;;^UTILITY(U,$J,358.3,18665,0)
;;=E11.22^^64^834^3
;;^UTILITY(U,$J,358.3,18665,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18665,1,3,0)
;;=3^DM Type 2 w/ CKD
;;^UTILITY(U,$J,358.3,18665,1,4,0)
;;=4^E11.22
;;^UTILITY(U,$J,358.3,18665,2)
;;=^5002630
;;^UTILITY(U,$J,358.3,18666,0)
;;=E11.42^^64^834^10
;;^UTILITY(U,$J,358.3,18666,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18666,1,3,0)
;;=3^DM Type 2 w/ Peripheral Neuropathy
;;^UTILITY(U,$J,358.3,18666,1,4,0)
;;=4^E11.42
;;^UTILITY(U,$J,358.3,18666,2)
;;=^5002646
;;^UTILITY(U,$J,358.3,18667,0)
;;=E11.43^^64^834^2
;;^UTILITY(U,$J,358.3,18667,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18667,1,3,0)
;;=3^DM Type 2 w/ Autonomic Neuropathy
;;^UTILITY(U,$J,358.3,18667,1,4,0)
;;=4^E11.43
;;^UTILITY(U,$J,358.3,18667,2)
;;=^5002647
;;^UTILITY(U,$J,358.3,18668,0)
;;=E11.51^^64^834^9
;;^UTILITY(U,$J,358.3,18668,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18668,1,3,0)
;;=3^DM Type 2 w/ Peripheral Angiopathy w/o Gangrene
;;^UTILITY(U,$J,358.3,18668,1,4,0)
;;=4^E11.51
;;^UTILITY(U,$J,358.3,18668,2)
;;=^5002650
;;^UTILITY(U,$J,358.3,18669,0)
;;=E11.52^^64^834^8
;;^UTILITY(U,$J,358.3,18669,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18669,1,3,0)
;;=3^DM Type 2 w/ Peripheral Angiopathy w/ Gangrene
;;^UTILITY(U,$J,358.3,18669,1,4,0)
;;=4^E11.52
;;^UTILITY(U,$J,358.3,18669,2)
;;=^5002651
;;^UTILITY(U,$J,358.3,18670,0)
;;=E11.621^^64^834^4
;;^UTILITY(U,$J,358.3,18670,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18670,1,3,0)
;;=3^DM Type 2 w/ Foot Ulcer
;;^UTILITY(U,$J,358.3,18670,1,4,0)
;;=4^E11.621
;;^UTILITY(U,$J,358.3,18670,2)
;;=^5002656
;;^UTILITY(U,$J,358.3,18671,0)
;;=E11.649^^64^834^6
;;^UTILITY(U,$J,358.3,18671,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18671,1,3,0)
;;=3^DM Type 2 w/ Hypoglycemia w/o Coma
;;^UTILITY(U,$J,358.3,18671,1,4,0)
;;=4^E11.649
;;^UTILITY(U,$J,358.3,18671,2)
;;=^5002662
;;^UTILITY(U,$J,358.3,18672,0)
;;=E11.65^^64^834^5
;;^UTILITY(U,$J,358.3,18672,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18672,1,3,0)
;;=3^DM Type 2 w/ Hyperglycemia
;;^UTILITY(U,$J,358.3,18672,1,4,0)
;;=4^E11.65
;;^UTILITY(U,$J,358.3,18672,2)
;;=^5002663
;;^UTILITY(U,$J,358.3,18673,0)
;;=E11.69^^64^834^7
;;^UTILITY(U,$J,358.3,18673,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,18673,1,3,0)
;;=3^DM Type 2 w/ Other Complications
;;^UTILITY(U,$J,358.3,18673,1,4,0)
;;=4^E11.69
;;^UTILITY(U,$J,358.3,18673,2)
;;=^5002664
;;^UTILITY(U,$J,358.3,18674,0)
;;=Z79.84^^64^834^13
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI15G 3753 printed Sep 23, 2025@19:38:07 Page 2
IBDEI15G ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,18661,2)
+2 ;;=^5003026
+3 ;;^UTILITY(U,$J,358.3,18662,0)
+4 ;;=E11.9^^64^834^11
+5 ;;^UTILITY(U,$J,358.3,18662,1,0)
+6 ;;=^358.31IA^4^2
+7 ;;^UTILITY(U,$J,358.3,18662,1,3,0)
+8 ;;=3^DM Type 2 w/o Complications
+9 ;;^UTILITY(U,$J,358.3,18662,1,4,0)
+10 ;;=4^E11.9
+11 ;;^UTILITY(U,$J,358.3,18662,2)
+12 ;;=^5002666
+13 ;;^UTILITY(U,$J,358.3,18663,0)
+14 ;;=E10.9^^64^834^1
+15 ;;^UTILITY(U,$J,358.3,18663,1,0)
+16 ;;=^358.31IA^4^2
+17 ;;^UTILITY(U,$J,358.3,18663,1,3,0)
+18 ;;=3^DM Type 1 w/o Complications
+19 ;;^UTILITY(U,$J,358.3,18663,1,4,0)
+20 ;;=4^E10.9
+21 ;;^UTILITY(U,$J,358.3,18663,2)
+22 ;;=^5002626
+23 ;;^UTILITY(U,$J,358.3,18664,0)
+24 ;;=Z79.4^^64^834^14
+25 ;;^UTILITY(U,$J,358.3,18664,1,0)
+26 ;;=^358.31IA^4^2
+27 ;;^UTILITY(U,$J,358.3,18664,1,3,0)
+28 ;;=3^Long Term Use of Insulin
+29 ;;^UTILITY(U,$J,358.3,18664,1,4,0)
+30 ;;=4^Z79.4
+31 ;;^UTILITY(U,$J,358.3,18664,2)
+32 ;;=^5063334
+33 ;;^UTILITY(U,$J,358.3,18665,0)
+34 ;;=E11.22^^64^834^3
+35 ;;^UTILITY(U,$J,358.3,18665,1,0)
+36 ;;=^358.31IA^4^2
+37 ;;^UTILITY(U,$J,358.3,18665,1,3,0)
+38 ;;=3^DM Type 2 w/ CKD
+39 ;;^UTILITY(U,$J,358.3,18665,1,4,0)
+40 ;;=4^E11.22
+41 ;;^UTILITY(U,$J,358.3,18665,2)
+42 ;;=^5002630
+43 ;;^UTILITY(U,$J,358.3,18666,0)
+44 ;;=E11.42^^64^834^10
+45 ;;^UTILITY(U,$J,358.3,18666,1,0)
+46 ;;=^358.31IA^4^2
+47 ;;^UTILITY(U,$J,358.3,18666,1,3,0)
+48 ;;=3^DM Type 2 w/ Peripheral Neuropathy
+49 ;;^UTILITY(U,$J,358.3,18666,1,4,0)
+50 ;;=4^E11.42
+51 ;;^UTILITY(U,$J,358.3,18666,2)
+52 ;;=^5002646
+53 ;;^UTILITY(U,$J,358.3,18667,0)
+54 ;;=E11.43^^64^834^2
+55 ;;^UTILITY(U,$J,358.3,18667,1,0)
+56 ;;=^358.31IA^4^2
+57 ;;^UTILITY(U,$J,358.3,18667,1,3,0)
+58 ;;=3^DM Type 2 w/ Autonomic Neuropathy
+59 ;;^UTILITY(U,$J,358.3,18667,1,4,0)
+60 ;;=4^E11.43
+61 ;;^UTILITY(U,$J,358.3,18667,2)
+62 ;;=^5002647
+63 ;;^UTILITY(U,$J,358.3,18668,0)
+64 ;;=E11.51^^64^834^9
+65 ;;^UTILITY(U,$J,358.3,18668,1,0)
+66 ;;=^358.31IA^4^2
+67 ;;^UTILITY(U,$J,358.3,18668,1,3,0)
+68 ;;=3^DM Type 2 w/ Peripheral Angiopathy w/o Gangrene
+69 ;;^UTILITY(U,$J,358.3,18668,1,4,0)
+70 ;;=4^E11.51
+71 ;;^UTILITY(U,$J,358.3,18668,2)
+72 ;;=^5002650
+73 ;;^UTILITY(U,$J,358.3,18669,0)
+74 ;;=E11.52^^64^834^8
+75 ;;^UTILITY(U,$J,358.3,18669,1,0)
+76 ;;=^358.31IA^4^2
+77 ;;^UTILITY(U,$J,358.3,18669,1,3,0)
+78 ;;=3^DM Type 2 w/ Peripheral Angiopathy w/ Gangrene
+79 ;;^UTILITY(U,$J,358.3,18669,1,4,0)
+80 ;;=4^E11.52
+81 ;;^UTILITY(U,$J,358.3,18669,2)
+82 ;;=^5002651
+83 ;;^UTILITY(U,$J,358.3,18670,0)
+84 ;;=E11.621^^64^834^4
+85 ;;^UTILITY(U,$J,358.3,18670,1,0)
+86 ;;=^358.31IA^4^2
+87 ;;^UTILITY(U,$J,358.3,18670,1,3,0)
+88 ;;=3^DM Type 2 w/ Foot Ulcer
+89 ;;^UTILITY(U,$J,358.3,18670,1,4,0)
+90 ;;=4^E11.621
+91 ;;^UTILITY(U,$J,358.3,18670,2)
+92 ;;=^5002656
+93 ;;^UTILITY(U,$J,358.3,18671,0)
+94 ;;=E11.649^^64^834^6
+95 ;;^UTILITY(U,$J,358.3,18671,1,0)
+96 ;;=^358.31IA^4^2
+97 ;;^UTILITY(U,$J,358.3,18671,1,3,0)
+98 ;;=3^DM Type 2 w/ Hypoglycemia w/o Coma
+99 ;;^UTILITY(U,$J,358.3,18671,1,4,0)
+100 ;;=4^E11.649
+101 ;;^UTILITY(U,$J,358.3,18671,2)
+102 ;;=^5002662
+103 ;;^UTILITY(U,$J,358.3,18672,0)
+104 ;;=E11.65^^64^834^5
+105 ;;^UTILITY(U,$J,358.3,18672,1,0)
+106 ;;=^358.31IA^4^2
+107 ;;^UTILITY(U,$J,358.3,18672,1,3,0)
+108 ;;=3^DM Type 2 w/ Hyperglycemia
+109 ;;^UTILITY(U,$J,358.3,18672,1,4,0)
+110 ;;=4^E11.65
+111 ;;^UTILITY(U,$J,358.3,18672,2)
+112 ;;=^5002663
+113 ;;^UTILITY(U,$J,358.3,18673,0)
+114 ;;=E11.69^^64^834^7
+115 ;;^UTILITY(U,$J,358.3,18673,1,0)
+116 ;;=^358.31IA^4^2
+117 ;;^UTILITY(U,$J,358.3,18673,1,3,0)
+118 ;;=3^DM Type 2 w/ Other Complications
+119 ;;^UTILITY(U,$J,358.3,18673,1,4,0)
+120 ;;=4^E11.69
+121 ;;^UTILITY(U,$J,358.3,18673,2)
+122 ;;=^5002664
+123 ;;^UTILITY(U,$J,358.3,18674,0)
+124 ;;=Z79.84^^64^834^13
